NeOnc Will Seek FDA Guidance on Brain Cancer Therapy
The company will meet with regulators in November 2026 to discuss development plans for a new brain cancer treatment candidate.
Updated on Sept. 28, 2026 in Cancer
Live Poll
Should the FDA use accelerated approval pathways more frequently for new, unproven brain cancer treatments?
NeOnc Technologies is set to meet with the FDA on November 17, 2026, at the agency's Silver Spring campus to refine its clinical development strategy for the drug candidate NEO212. This meeting follows the successful completion of a Phase 1 dose-escalation trial that studied outcomes in patients with glioblastoma and lung cancer metastasized to the brain.
Why it matters
This meeting is a critical step for determining the registrational path, including potential accelerated approval, for a therapy currently under investigation for aggressive brain tumors. It will define the necessary evidence for a future marketing application to bring this treatment closer to clinical practice.
In Phase 1 clinical testing, NeOnc observed a 60% tumor reduction in one glioblastoma patient and 16 months of stable disease in a patient with lung cancer metastatic to the brain. Researchers established 610 mg as the recommended dose for Phase 2 trials after discontinuing an 810 mg level due to toxicity.
The players
NeOnc Technologies
A biotechnology company based in Calabasas, California, focused on developing novel therapies for glioblastoma and other metastatic brain cancers.
FDA
The United States federal agency responsible for regulating pharmaceuticals and clinical trial designs to ensure safety and efficacy.
The details
The drug candidate NEO212 is being evaluated for its potential to treat cancers that affect the brain, with the current protocol utilizing a 28-day cycle where the drug is administered once daily for the first five days. During the dose-escalation phase, researchers monitored for dose-limiting toxicities, which led to the selection of the 610 mg dose to optimize the safety and efficacy profile for upcoming Phase 2a and 2b trial portions.
Timeline
September 2025: The FDA authorized the progression of NEO212 into Phase 2a and 2b trial stages.
September 28, 2026: The company announced the date for its upcoming regulatory meeting.
November 17, 2026: NeOnc is scheduled to meet with the FDA at the agency's White Oak campus.
Health Landscape
The development of NEO212 follows the established FDA End-of-Phase 1 meeting process, which allows manufacturers to synchronize their late-stage trial designs with regulatory expectations. This strategic milestone is standard in oncology to ensure that the clinical endpoints align with the evidence required for future marketing authorization.
For patients following research in brain tumor therapies, this meeting signifies a transition toward more rigorous clinical evaluation. It is worth discussing with your doctor how clinical trial eligibility is determined and what standard-of-care options remain available while these new therapies are in development.
The takeaway
This regulatory update marks a progression in the clinical testing of a promising brain cancer therapy. Patients and families should continue to monitor updates on clinical trial registration sites, as these are the primary mechanisms for access to experimental treatments.
What happens next
NeOnc plans to finalize its registrational development strategy and potential accelerated approval pathways following the feedback received during the November 17, 2026 meeting.
Further reading
For broader context on current clinical advancements, explore the latest research and regulatory milestones in our Cancer section.
More information
For more details on the company's research pipeline, visit the NeOnc official company information website.
Live Poll
Should the FDA use accelerated approval pathways more frequently for new, unproven brain cancer treatments?
